Epilepsy in neurodegenerative diseases

Sabrina Neri1,2, Giovanni Mastroianni3, Elena Gardella1, Umberto Aguglia2,3, Guido Rubboli1

1 Danish Epilepsy Centre, Dianalund, Denmark
2 Department of Medical and Surgical Sciences, “Magna Graecia” University, Catanzaro, Italy
3 Regional Epilepsy Centre, Great Metropolitan Hospital, Reggio Calabria, Italy

ABSTRACT
Although epilepsy as a comorbidity in neurodegenerative disorders is increasingly recognized, its incidence is still underestimated and the features of epilepsy in the different neurodegenerative conditions are still poorly defined. Improved health care, resulting in increased longevity, will unavoidably lead to an increment of epilepsy cases in the elderly. Thus, it is conceivable to expect that neurologists will have to deal with these comorbid conditions to a growing extent in the future. In this seminar, we provide an updated overview of the clinical features, pathophysiological mechanisms and diagnostic and treatment approaches of epilepsy in the most common neurodegenerative disorders (such as Alzheimer disease and other types of dementia, Parkinson disease, Down syndrome, prion diseases, and progressive myoclonic epilepsies), aiming to provide a tool that can help epileptologists and neurologists in the diagnosis and management of this increasingly reported comorbidity.

Key words: neurodegenerative disease, epilepsy, prion disease, Alzheimer disease, Parkinson disease, late-onset myoclonic epilepsy in Down syndrome

Neurodegenerative disorders are a group of conditions characterized by selective neuronal loss and by a progressive course and chronic evolution that lead to a gradual deterioration of functions. The spectrum of neurodegenerative diseases encompasses a large number of different entities with variable epidemiology, clinical manifestations, neuropathology and management [1].

The incidence of neurodegenerative disorders varies across different age groups with two age peaks in children/young adults and in the elderly. The most common causes of degenerative diseases with onset in the first two/three decades of life are genetic...
disorders, most of them producing neuronal damage or neurotransmitter alterations. In the elderly, age is the major risk factor associated with neurodegenerative conditions, such as Alzheimer or Parkinson diseases, vascular dementia or other dementia conditions of old age [2]. Epilepsy can be a comorbidity in a large variety of neurological disorders including neurodegenerative diseases [3]. Although the individual risk of epilepsy can vary significantly in the different neurodegenerative conditions, the possibility of a comorbid epilepsy has to be considered when evaluating a patient suffering from these disorders and presenting with episodes of possible epileptic nature, since the potential benefits from early diagnosis are high. Indeed, a prompt diagnosis in younger subjects can help achieve better cognitive development and quality of life outcomes, whereas in older patients, a better seizure control can minimize cognitive deficits and prevent morbidity from falls or other seizure-related injuries, in addition to enabling medical and legal assistance for complex decision making in their advanced ages. Older age represents an independent risk factor in neurodegenerative diseases [4] and epilepsy [5]. Epilepsy occurs in about 1% of patients aged more than 65 years (about one quarter of newly diagnosed epilepsies) [2, 6]. In this age group, the most common pathologies underlying seizures are cerebrovascular diseases, brain tumours, traumatic brain injury and neurodegenerative disorders [4]. For these latter conditions, epidemiologic data, although scarce, indicate that they might account for about 10% of late-onset epilepsies [2]. Due to the lack of anatomical or biochemical markers for the neurodegenerative diseases at their onset, the recognition of a causal relationship between epilepsy and a degenerative condition is possible only in retrospect, when this latter disease becomes clinically evident. It is thus possible that a proportion of late-onset epilepsies classified as cryptogenic are instead related to neurodegenerative pathologies [7], suggesting also that the 10% figure emerging from studies mentioned above might underestimate the etiologic role of degenerative pathologies in epilepsy in the elderly. This consideration may advocate the inclusion of a comprehensive cognitive assessment for elderly patients with an initial seizure and negative etiologic investigation to yield an early diagnosis. In this paper, we present an updated overview of the clinical features, diagnostic procedures and pathogenetic mechanisms of epilepsy in the most common degenerative diseases, aiming to provide a tool that can help epileptologists and neurologists in the diagnosis and management of this increasingly reported comorbidity.

Neurodegenerative disorders and epilepsy: clinical features, diagnostic procedures, and pathogenetic mechanisms

Alzheimer disease

Alzheimer disease (AD) accounts for 60-70% of all dementia cases [8]. The accumulation of extracellular aggregates of amyloid β (Aβ) plaques and intracellular neurofibrillary tangles (NFTs) made of hyperphosphorylated tau-protein in cortical and limbic areas of the human brain is considered to play a major role in the neurodegenerative processes occurring in the brain of AD patients, as proposed by the amyloid hypothesis [9], even though other complex and multiple factors have been recently shown to participate in the development of dementia [10]. The first description of epileptic seizures in a confirmed AD patient is ascribed to Hannah in 1936 [11] although, in 1911, Alzheimer himself had already reported a patient with probable seizures and with amyloid deposition in the brain as the only pathological marker [12]. It is now widely accepted that seizures can occur in AD patients [13] and that AD-related pathological changes might be a causative factor for late-onset unprovoked seizures [14].

- Epidemiology and modifying risk factors for seizures

The lifetime prevalence of seizures in AD patients varies in different studies depending on the sampled population or on whether they are retrospective or prospective. Although some reviews report a prevalence ranging from 10% to 22% [13, 15], the accuracy of these studies may be limited by the variability of the inclusion criteria that might have led to the inclusion of patients with other forms of dementia or other symptomatic causes of epilepsy in the elderly, besides pathologically confirmed AD [16]. The probability of developing seizures after AD onset has been estimated to be 13.4% [17], while a study on mild AD patients with a follow-up of seven years reported a cumulative incidence of unprovoked seizures of 8% [18]. Compared to healthy age-matched individuals, patients with sporadic AD have a two to ten-fold increased risk of manifesting seizures during the course of their illness [19]. Recently, a study analysing data from the Framingham Heart Study (FHS) showed a two-fold increase in risk for dementia among prevalent cases of epilepsy compared to controls, and a similar increase in risk of subsequent epilepsy among people with diagnosed dementia [20]. Similarly, the Atherosclerosis Risk in Communities (ARIC) study reported a three-fold increase in risk for new-onset epilepsy among people with dementia as well as a three-fold elevated risk of developing dementia in patients with late-onset epilepsy [21].
An increased risk of developing seizures has been observed in patients with younger age at AD onset [18]. About 15% of patients with early-onset AD have mutations in presenilin-1 (PSEN1), presenilin-2 (PSEN2), or amyloid protein precursor (APP) genes [22]. Around 20% of PSEN1 pathogenic variants have been reported to be associated with seizures, prompting the proposal to recognize a PSEN1-associated genetic epilepsy syndrome [23]. Moreover, seizures can occur in carriers with mutations in autosomal dominant AD genes even if they are cognitively asymptomatic [24]. However, the occurrence of seizures may be underestimated, since in clinical practice the detection of seizures and the description of their semiology is based largely on information reported by the patient him/herself or by the caregiver. The impairment of memory in patients with dementia or the difficulties experienced by a caregiver in distinguishing fluctuating behavioural manifestations, common in demented patients, from focal seizures, may significantly hinder the recognition of epilepsy as a comorbidity or the evaluation of its severity.

Several studies have shown that seizure prevalence in AD seems to increase with disease duration [13, 25]. The mean interval from diagnosis of AD to seizure onset is reported to range from 3.6 years [25] to 6.8 years [26]. However, a seizure onset early in the course of the disease, even in stages preceding the onset of cognitive decline, has been documented as well, probably reflecting the well-established concept that the neuropathological alterations of Alzheimer disease precede the onset of symptoms [27]. A clinically-based study on newly diagnosed probable-AD patients revealed a history of seizure disorder in 6.8% of them [28]. In 3.4% of cases, seizure onset was time-locked to the onset of cognitive decline, and no symptomatic or provoking factor for seizures other than AD was identified [28]. Based on retrospective studies reviewing the prevalence of adult-onset epilepsy in a large population of AD patients, seizure onset was reported, on average, 4.6 years before the detection of cognitive symptoms [29].

These pieces of evidence have led to a debate on the existence of an inaugural epilepsy syndrome in sporadic AD that might define an “epileptic variant” of AD [30]. At present, however, according to the IWG-2 criteria for the diagnosis of AD, early occurrence of seizures remains an exclusion criterion for typical AD [31].

**Seizure semiology**

Focal seizures with impaired awareness with or without secondary generalization are the most common seizure type reported in up to 90% of AD patients [13]. However, subtle non-convulsive seizures without overt clinical symptoms may likely pass unrecognized and thus be under-reported. A study designed to identify possible ictal symptoms/signs compatible with epileptic seizures in a population with AD and mild cognitive impairment [32] identified multiple seizure-related features, such as altered responsiveness, speech/behavioural arrest, oral automatism, olfactory/gustatory aura, focal motor phenomena, other sensory symptoms (including hallucination) and amnesic episodes on awakening, suggesting that the most common of these manifestations might easily not be reported by caregivers because these are considered a feature of underlying dementia.

Transient epileptic amnesia (TEA), sporadically reported in the early stages of AD, has been suggested as a possible cause of wandering behaviour in AD patients [33]. Non-convulsive status epilepticus, even if occasional and rare, has also been described [34].

**EEG**

EEG, and in particular longitudinal EEGs, are not part of the usual clinical work-up in dementia patients. Non-epileptiform abnormalities such as theta or delta slowing are common EEG features of AD patients [35], but little information exists about the prevalence and diagnostic value of epileptiform abnormalities. In a large study [36] on individuals with different types of dementia, epileptiform EEG discharges were found in only 3% of the patients, which is a rate similar to that of the general population. Only 10% of the AD patients with epileptiform activity on EEG developed seizures later on during the course of the disease [36]. However, in another investigation on 33 AD subjects without a history of seizures, subclinical epileptiform activity was detected in 42.4% of patients and 10.5% of controls [37]. Finally, a study with foramen ovale electrodes showed that clinically silent mesial temporal lobe seizures and epileptic spikes, predominating during sleep (thus possibly interfering with memory consolidation), can be detected early in the course of AD, in the absence of significant scalp EEG abnormalities [38], further suggesting that epileptic activity or seizures may be undetected in a proportion of AD patients. All these data cast some doubt on the value of the standard scalp EEG in diagnosing epilepsy in AD patients and emphasize the need for larger longitudinal EEG studies, perhaps using additional techniques, including foramen ovale recordings, to determine the EEG diagnostic value in clinical practice.

**Pathophysiology of seizures in AD and impact on cognitive functions**

The pathophysiological mechanisms underlying epilepsy in AD are still incompletely elucidated. Experimental studies have shown that mice with APP
mutations exhibit not only high levels of amyloid-beta (Aβ) peptides in the brain and develop AD-like clinical and pathological abnormalities, but also have spontaneous non-convulsive seizure activity in cortical and hippocampal networks [39]. Moreover, video-EEG monitoring of the cortical and hippocampal activity in human amyloid precursor protein transgenic (hAPP) mice, without evidence of neuronal loss, showed abundant epileptiform activity, suggesting that the exposure to pathologically relevant levels of Aβ may be sufficient to elicit aberrant network synchronization, epileptiform activity and seizures, even in the absence of frank degeneration [40]. Epileptic discharges trigger inhibitory rescue responses in hippocampal circuits that may contrast Aβ-induced aberrant network activity but also interfere with normal neuronal functions required for memory formation and learning [41]. Therefore, cognitive decline and epilepsy can reciprocally influence one another in AD and may possibly share some common pathophysiological mechanisms, suggesting that treating epilepsy, or if possible preventing it, could be an important new approach to slow down cognitive decline in selected patients with Aβ pathology. Moreover, hyperphosphorylated tau aggregates and NFTs have been observed in several patients with epilepsy [42] and pathologic tau has been correlated with epilepsy in animal models [43].

- **Therapy**

Antiseizure medications (ASMs) seem to prevent the recurrence of epileptic seizures in most people with Alzheimer disease, however, other factors such as drug-drug interactions, pharmacodynamics and adverse effects on cognition and behaviour should be taken into account for the treatment of seizures in AD patients. Long-term use of benzodiazepines is associated with an elevated risk of cognitive decline or dementia [44]. Valproic acid has been associated in clinical trials with a faster decline in Mini-mental state examination (MMSE) scores and more pronounced atrophy on brain imaging [45]. Lamotrigine, which is considered a viable option for treating seizures in patients with AD, may exacerbate myoclonus in AD patients, especially those with PSEN1 mutations [23]. A recent Cochrane review investigating the efficacy and tolerability of pharmacological or non-pharmacological interventions for the treatment of epilepsy based on randomized and quasi-randomized controlled trials revealed no significant differences in seizure freedom for comparisons between levetiracetam versus lamotrigine, levetiracetam versus phenobarbital, or lamotrigine versus phenobarbital. Additional findings suggested that levetiracetam could improve cognition and lamotrigine could relieve depression, while phenobarbital and lamotrigine could worsen cognition, and levetiracetam and phenobarbital could worsen mood [47]. However, the level of evidence of these results was very low and the study failed to show significant differences in efficacy and tolerability between levetiracetam, phenobarbital and lamotrigine [47]. In conclusion, at present, there is insufficient evidence to support which ASM should be recommended to treat seizures in AD.

**Case 1**

An 89-year-old woman with chronic renal failure, diabetes and hypertension was diagnosed with Alzheimer’s dementia at the age of 85 years. Neuropsychological evaluation showed deficits in executive functions, sustained attention and semantic and procedural memory; Mini-Mental State Examination score was 16 (normal range: 26-30). At the age of 89 years, she was admitted to the hospital because of an acute onset of “tremors” in the right upper limb, then spreading to the ipsilateral lower limb, without loss of consciousness, although she had difficulties in answering questions and executing simple orders. A CT scan and a biochemical work-up were unremarkable. During admission, the episodes of unilateral clonic jerking on the right side became progressively more frequent and consciousness was impaired which did not recover in the intervals between seizures.

The EEG showed continuous spikes and spike-waves at the bifrontal leads, with left prevalence associated with myoclonus of the right limbs (figure 1A). A diagnosis of focal motor status epilepticus was made. The administration of 5 mg of midazolam IV was followed by EEG normalization (figure 1B), disappearance of the clonic jerks and recovery of consciousness. Chronic antiepileptic therapy with levetiracetam was undertaken. The patient was seizure-free at a six-month follow-up consultation.

**Case notes:** This example illustrates a case of epilepsy comorbidity in AD. This patient presented with an isolated episode of focal motor status epilepticus that occurred four years after the onset of dementia, in agreement with data in the literature, which report an average interval of 3.6 years between the diagnosis of AD and the appearance of epileptic seizures. The focal status epilepticus was diagnosed based on the clinical features, the ictal EEG and electroclinical response to therapy. The patient started treatment with levetiracetam and she did not present further seizures during follow-up.
Down syndrome and late-onset epilepsy

Down syndrome (DS), the most common chromosomal disorder in humans, is due to trisomy of chromosome 21. Seizures or epilepsy, not reported in the first description of the disease [48], are known to have a higher prevalence (from one to 13%) than in the general population [49].

The onset of seizures follows a bimodal distribution, with 40% of DS patients presenting with epilepsy in infancy or early childhood, mainly with epileptic spasms and tonic seizures, and another 40% who start to suffer from epilepsy in the third decade of life [49], when Down patients start to be affected by a dementing process.

Autopsy studies demonstrated that neuropathological features of Alzheimer can be observed in the brain of DS patients from the age of 37 years [50], while the average age at onset of dementia is between 50 and 55 years [51]. According to a neuropathological hypothesis, triplication of the $\text{APP}$ gene, located on chromosome 21, leads to amyloid overproduction. The extracellular accumulation of amyloid plaques induces synaptic degeneration, circuit remodelling and abnormal synchronization of neuronal networks, resulting in cortical irritability, thus with an epileptogenic mechanism similar to AD [52].

Accompanying or closely following the appearance of neurological deterioration, more than 50% of patients with DS and AD dementia will most likely develop epilepsy. The prevalence of untriggered seizures in DS increases dramatically after the age of 45 years, anticipating or in parallel with the emergence of cognitive deterioration. The prevalence of epilepsy can be as high as 46% in those over 50 years of age [53].

Myoclonic seizures are the most common seizure type, involving the limbs and the trunk. At onset, myoclonic seizures predominantly present in the morning, and polygraphic recordings show myoclonic bursts associated with generalized spike-wave discharges, as in juvenile myoclonic epilepsy [54]. Myoclonic seizures can occur in clusters, but massive and/or fall-inducing
myoclonus are infrequent [54]. Generalized tonic-clonic seizures may appear at a later stage [55], as well as photoparoxysmal EEG responses [56]. Focal seizures with an altered level of consciousness without a motor component, the most frequent type of epileptic seizure in sporadic AD, occur rarely in DS [49]. This epileptic disorder, with predominant myoclonic features occurring in DS patients with dementia, has been proposed to represent a specific entity, labelled as “late-onset myoclonic epilepsy in DS” (LOMEDS) [57]. LOMEDS appears, on average, 6.9 months after the onset of dementia and exhibits a clinical course similar to that of progressive myoclonus epilepsies, with myoclonus becoming more severe over time and resistant to treatment, in parallel with progressive cognitive decline [56]. The development of multifocal epileptic and non-epileptic (i.e., action) myoclonus, sometimes induced by movements or less frequently by sensory stimulus (i.e., reflex epileptic myoclonus), increases the risk of falls. In the more advanced stages, myoclonia inconstantly display an EEG correlate [53], suggesting a non-cortical origin, and tremor and disabling cerebellar ataxia appear, worsening relentlessly [51]. The occurrence of epileptic seizures in DS has been associated with a more rapid cognitive and functional decline [51]. Epilepsy is also an independent risk factor for more frequent hospital admissions and mortality in adults with DS [53]. A study showed valproate and levetiracetam to be effective in controlling myoclonic seizures in adults with DS [53]. A study showed valproate and levetiracetam to be effective in controlling myoclonic and generalized tonic-clonic seizures in about 80% of patients [54]. An overview of published cases with LOMEDS is presented in table 1.

**Prion diseases**

Prionopathies are a group of rare, fatal neurodegenerative diseases characterized by progressive dementia and focal neurological signs. The pathogenic hallmark of these conditions is the aggregation and accumulation of an abnormally folded protein termed PrPSc, which differs from the normal protein (PrPC) due to a high number of β-pleated sheets in the secondary structure compared to normal α-helices. This conformation renders the protein capable of resisting protease degradation. The prion protein can also determine the conversion of normal PrPC to PrPSc, causing an accumulation in certain populations in neurons, leading to vacuolation, astrocytosis, development of amyloid plaques and neuronal loss. Sporadic, genetic and acquired forms of prion diseases have been described [58].

Sporadic Creutzfeldt-Jakob disease (sCJD) is the most common prion disease, accounting for about 85% of CJD cases, with an incidence of one to two cases per one million population per year [59]. Autosomal dominant CJD is the next most common, caused by mutations in the PNRP gene, encoding for the prion protein. The rarest forms are those that are acquired, such as kuru, iatrogenic CJD and variant CJD (vCJD) [58].

Current data on epilepsy in prion diseases are based on small series or individual case reports, in which epilepsy is often superficially described. Overall, epilepsy appears to be a very rare comorbidity in prionopathies. In sCJD, seizures can occur during the course of the disease in about 8% of subjects [3]. Seizures, as the presenting symptom of sCJD, are even rarer, occurring in only about 3% of cases [60].

The inherited forms of the disease, caused by mutations of the PRNP gene at chromosome 20, include Gerstmann-Sträussler-Scheinker disease (GSS), familial insomnia (FFI) and familial CJD. For familial CJD, the most common mutation is the E200K point mutation. In this latter type of CJD, seizures have been reported to occur in up to 40% of individuals [61].

Iatrogenic cases are caused by neurosurgical instruments, implantation of stereotactic electroencephalogram electrodes or by transplanted human tissues (dura mater grafts, corneas), contaminated by PrPSc protein. In contrast to what has been observed in sporadic and genetic cases, in iatrogenic CJD, seizures are exceptional or completely absent [62].

To our knowledge, no reports of seizures exist in the acquired form of prion disease, kuru, while focal motor seizures have been described in only one case with variant CJD [63].

In patients with prionopathies and epilepsy, seizure onset may precede the onset of typical symptoms by a few weeks [64]. However, the recognition of epilepsy as a presenting symptom may be overlooked, due to the difficulties in distinguishing, at disease onset, dyscognitive or psychiatric symptoms from subtle non-motor seizures with impaired awareness. In almost half of the patients reported in the literature, non-convulsive status epilepticus is the most frequently reported type of seizure, followed by focal aware seizures with motor phenomena (often myoclonic jerks of the limbs), focal seizures with impaired awareness, focal motor status epilepticus (epilepsia partialis continua), convulsive status epilepticus and focal to bilateral tonic-clonic or generalized motor seizures.

The physiopathogenetic mechanisms underlying epilepsy in prion diseases are still poorly elucidated. Studies in vivo have demonstrated that deletion of the PrPSc gene in mice enhances neuronal excitability and seizure sensitivity by disrupting Ca2+-activated K+ currents, generating abnormal GABA-A inhibition in the hippocampus and/or higher levels of neocortical and subcortical oxidative stress [65]. Loss of PrPC function [66] due to conversion to, or contact with
Table 1. Overview of published cases with late-onset myoclonic epilepsy in Down syndrome (LOMEDS).

<table>
<thead>
<tr>
<th>Reference</th>
<th>Sex (M/F)</th>
<th>Age at observation mean (range)</th>
<th>Age at dementia onset mean (range)</th>
<th>Age at seizure onset mean (range)</th>
<th>Seizure type</th>
<th>EEG</th>
<th>Imaging</th>
<th>ASMs</th>
<th>Seizure response to ASMs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Li et al. [97]</td>
<td>1/0</td>
<td>51</td>
<td>NA</td>
<td>50</td>
<td>M, TC</td>
<td>Diffuse slowing, diffuse Sp-W</td>
<td>NA</td>
<td>CBZ, VPA</td>
<td>SR after VPA</td>
</tr>
<tr>
<td>Moller et al. [98]</td>
<td>1/0</td>
<td>55</td>
<td>NA</td>
<td>52</td>
<td>M, TC</td>
<td>Diffuse slowing; diffuse Sp-W, PoliSp-W</td>
<td>Cortical atrophy</td>
<td>VPA, LTG, TPM</td>
<td>SR after TPM</td>
</tr>
<tr>
<td>De Simone et al. [99]</td>
<td>1/1</td>
<td>44y/(33-55)</td>
<td>50y (50)</td>
<td>44,5y (33-56)</td>
<td>M, TC, focal impaired awareness</td>
<td>Diffuse slowing, diffuse Sp-W, PoliSp-W, focal Sp and fast Sp-W, photoparoxysmal response</td>
<td>Mild brainstem and subcortical atrophy</td>
<td>CBZ, LEV, VPA</td>
<td>M improved after LEV and VPA</td>
</tr>
<tr>
<td>Crespel et al. [100]</td>
<td>1/1</td>
<td>NA</td>
<td>NA</td>
<td>52,5y (50-55)</td>
<td>GTC, M</td>
<td>BG disorganization, SharpSW, Fast Sp, generalized Sp and PoliSp</td>
<td>Severe cortical atrophy with ventricular enlargement</td>
<td>LEV, VPA, LTG</td>
<td>SR after LEV and VPA</td>
</tr>
<tr>
<td>De Simone et al. [101]</td>
<td>6/12</td>
<td>49,1y (29-61)</td>
<td>48,16y (36-59)</td>
<td>49,61y (36-59)</td>
<td>M, GTC</td>
<td>Generalized and focal Sp-W and PoliSp-W, photoparoxysmal response, diffuse slowing</td>
<td>Diffuse atrophy</td>
<td>VPA, LEV, TPM, LTG, PIR</td>
<td>SR after ASMs</td>
</tr>
<tr>
<td>Sangani et al. [102]</td>
<td>2/0</td>
<td>48y (44-52)</td>
<td>48y (44-52)</td>
<td>48,5y (45-52)</td>
<td>M</td>
<td>Slow BG, generalised Sp and PoliSp-W</td>
<td>NA</td>
<td>PHT, LEV</td>
<td>Resolution/ improvement of M after LEV</td>
</tr>
<tr>
<td>Vignoli et al. [54]</td>
<td>11/11</td>
<td>46y (28-64)</td>
<td>NA</td>
<td>36,7y (6-60)</td>
<td>M, focal motor, tonic, GTC, reflex seizures, focal motor SE, focal with impaired awareness,</td>
<td>Slow BG, Sp-W and PoliSp-W, slow focal activity</td>
<td>Basal ganglia calcification, cortico subcortical atrophy, hydrocephalus, arachnoid cyst</td>
<td>VPA, PB, CBZ, GVG, CLB, LTG, TPM, TGB, PB, PRM, LEV, CNZ</td>
<td>SR in 18/22 patients</td>
</tr>
<tr>
<td>d’Orsi et al. [56]</td>
<td>5/7</td>
<td>54,5y (45-70)</td>
<td>51y (43-65)</td>
<td>51,4y (43-68)</td>
<td>M, T</td>
<td>Diffuse slowing, diffuse Sp-W, PolySp-W, photoparoxysmal response</td>
<td>Cerebral atrophy, hydrocephalus</td>
<td>TPM, LTG, LEV, OXC, VPA, CBZ, PB</td>
<td>Seizure reduction in 9/12 patients</td>
</tr>
</tbody>
</table>

M: myoclonic; TC: tonic-clonic; GTC: generalized tonic-clonic; SE: status epilepticus; Sp-W: Spike-wave; Sp: spike; BG: background; SW: slow waves; ASMs: anti-seizure medications; CBZ: carbamazepine; VPA: valproate; LTG: lamotrigine; TPM: topiramate; LEV: levetiracetam; PIR: piracetam; PHT: phenytoin; PB: phenobarbital; GVG: vigabatrin; CLB: clobazam; TGB: tiagabine; PRM: primidone; CNZ: clonazepam; OXC: oxcarbazepine; NE: no effect; SR: seizure reduction; AE: adverse event; SF: seizure freedom; NA: not available.
PrP\textsuperscript{sc} and toxic processes due to propagation of abnormal PrP\textsuperscript{sc} may contribute to destabilize local circuits and generate hyperexcitable and synchronized epileptogenic networks. The typical electroencephalographic findings in prion diseases are periodic sharp-wave complexes (PSWC, otherwise known as triphasic waves or TWs), which can be found in all types of prion diseases, but the new variant (vCJD) [67]. PSWCs are frequently bilaterally distributed but may appear, especially in the first stages of the disease, lateralized, resembling periodic lateralized epileptiform discharges (PLEDs) [68]. PLEDs have been described in CJD patients with focal motor seizures [69], focal motor status epilepticus [70] and focal non-convulsive status epilepticus [71]. Different criteria for diagnosing seizures in CJD have been used, such as correlating the EEG patterns with the clinical manifestations (i.e. in focal motor seizures) [70] or altered mental status [72], assessing the electrophysiological improvement after ASM administration or evaluating the evolution and variability of EEG patterns during prolonged recordings [72]. However, the reliability of EEG recordings in diagnosing seizures in CJD is still debated [73], especially to discriminate between non-convulsive status epilepticus (NCSE) and the typical alterations of consciousness observed in the late stages of the disease, since a misdiagnosis of refractory non-convulsive status epilepticus can lead to an aggressive but unnecessary therapeutic approach. Indeed, it is still discussed whether, in CJD, EEG abnormalities suggestive of NCSE reflect true seizure activity or whether they are PSWCs. Higher frequency (2.4 Hz vs 1.8 Hz) of the epileptiform activity and clinical-EEG improvement after benzodiazepine administration have been considered to be compatible with NCSE. In some instances, serial or prolonged EEGs can be necessary to establish the correct diagnosis [73].

In polygraphic and video EEG recordings of 109 sCJD patients [74], myoclonic jerks were observed in 50% of the subjects. PSWCs were detected in all but one patient with myoclonic jerks, and they were time-locked to the EMG myoclonic bursts only in the case of periodic myoclonus, supporting studies that demonstrated primarily a subcortical origin of myoclonus in the terminal stage of CJD. Anecdotal neuroimaging studies in patients with sporadic and variant CJD, besides the MRI findings that characterize CJD (such as abnormal diffusion in the cortex, caudate, and/or putamen and abnormal FLAIR cortical hyperintensities), have shown alterations compatible with prolonged seizures or status epilepticus as well as peri-ictal changes in the cerebral cortex, hippocampi and thalamus (particularly the pulvinar region), or cortical and gyriiform diffusion signal hyperintensity with cortical ribbon oedema [75].

Published data on treatment show that most of the cases failed to respond to ASM and only a minority of subjects had a partial improvement (table 2). In particular, in most of the patients, non-convulsive status epilepticus was refractory to second and third lines of treatment (table 2). At present, no evidence is available to indicate which ASM is the most effective, however, due to the high prevalence of focal seizures, levetiracetam and lamotrigine are the drugs most often used.

Case 2

A 69-year-old woman without any significant antecedent and without a family history of neurological disorders was admitted to the hospital because of progressively worsening difficulties of speech, loss of fine motor dexterity in the right arm, unstable gait and difficulties in maintaining an upright posture without support. Her symptoms had started two weeks prior to admission. A CT scan was unremarkable. The EEG at admission showed slowing of the background activity with some diffuse slow slow waves (figure 2A). Five days after hospitalization, she started to present with multiple daily episodes characterized by left head turning, stiffening of all four limbs and left limb clonic jerking. These episodes, initially stopped by administration of midazolam IV, recurred in the following days, sometimes spreading to the right limbs. An EEG 10 days after the first EEG, showed diffuse 1-2-Hz periodic sharp-wave complexes (figure 2B). Administration of midazolam IV did not modify the EEG. Chronic antiepileptic therapy with levetiracetam was undertaken with minimal and fluctuating improvement of seizures. Analysis of the CSF identified the presence of 14-3-3 protein (an non-specific marker of neuronal damage in prion disease). Real-time quaking-induced conversion (RT-QuIC) detected prion proteins in the CSF. These results prompted the diagnosis of probable sporadic CJD. During the following weeks, the patient developed global aphasia, aplanistic response to painful stimuli, head deviation to the left, right facio-brachio-crural hemiparesis, and dystonic head and left limb posture. She died three months after the onset of the symptoms.

Case notes: The case described here is an example of probable sporadic Creutzfeldt-Jakob disease (according to the clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease) presenting with seizures a few days after the onset of the clinical symptoms. The patient presented with focal motor seizures, which are reported to be among the most common seizure types in prion diseases (see table 2). Seizures responded only partially to levetiracetam therapy.
### Table 2. Overview of published cases with prion diseases and epilepsy.

<table>
<thead>
<tr>
<th>Reference</th>
<th>Sex (M/F)</th>
<th>Age at observation</th>
<th>Diagnosis</th>
<th>Seizure type</th>
<th>Epilepsy as presenting symptom?</th>
<th>Treatment</th>
<th>Response to treatment</th>
<th>EEG</th>
<th>Imaging (MRI)</th>
<th>Clinical course/ follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yang et al. [64]</td>
<td>M</td>
<td>62</td>
<td>Probable sporadic CJD</td>
<td>Unilateral clonic jerks (EPC); GTC during coma</td>
<td>Yes</td>
<td>VPA, TPM</td>
<td>Partial</td>
<td>Onset: focal discharges. Follow-up: generalized PSWC</td>
<td>DWI increased signal in bilateral F-P, right I and O cortex, bilateral caudate nuclei and putamen</td>
<td>Death after 5 months from EPC onset</td>
</tr>
<tr>
<td>Williams et al. [103]</td>
<td>F</td>
<td>71</td>
<td>Sporadic CJD</td>
<td>Occasional myoclonic jerking of the limbs</td>
<td>No</td>
<td>PHT, VPA</td>
<td>NA</td>
<td>Onset: sharpened SW, periods of suppressed EEG activity. Day 43: PSWC followed by suppression</td>
<td>FLAIR hyperintensities in caudate and basal ganglia, cortical ribbon-like high signal change</td>
<td>Death seven weeks after onset.</td>
</tr>
<tr>
<td>Taskiran et al. [104]</td>
<td>M</td>
<td>71</td>
<td>Probable sporadic CJD</td>
<td>Myoclonic jerks of right hand</td>
<td>Yes</td>
<td>LEV</td>
<td>Partial</td>
<td>PLEDs on the left F-C-T regions</td>
<td>DWI hyperintensities in bilateral caudate nuclei; left F, T, P cortex</td>
<td>Death after 2 months from onset</td>
</tr>
<tr>
<td>Shapiro et al. [105]</td>
<td>F</td>
<td>71</td>
<td>Sporadic CJD</td>
<td>NCRSE</td>
<td>Yes</td>
<td>PHT, VPA, PB, LEV, MDZ</td>
<td>Relapse of SE after MDZ weaning</td>
<td>Unilateral repetitive sharp-W, sometimes seen bilaterally, consistent with NCSE</td>
<td>Atrophy, restricted diffusion in left F lobe</td>
<td>Dead after 36 days from admission</td>
</tr>
<tr>
<td>Parry et al. [106]</td>
<td>F</td>
<td>67</td>
<td>Sporadic CJD</td>
<td>Myoclonic jerks of upper left limb and then left leg, GTC.</td>
<td>Yes</td>
<td>PHT, CLZ, VPA, LTG</td>
<td>None</td>
<td>Onset focal slow-W. After 2 weeks: prominent theta activity, intermittent bilateral delta activity, intermittent irregular focal sharp W. After 1 month: PLEDs</td>
<td>NA</td>
<td>Death after 3 months from seizure onset</td>
</tr>
<tr>
<td>Rees et al. [107]</td>
<td>F</td>
<td>58</td>
<td>Sporadic CJD</td>
<td>NCSE</td>
<td>No</td>
<td>VPA, PHT</td>
<td>None</td>
<td>Focal continuous sharp W, consistent with NCSE</td>
<td>NA</td>
<td>Died 3 weeks after onset of SE</td>
</tr>
<tr>
<td>Rees et al. [107]</td>
<td>M</td>
<td>68</td>
<td>Probable sporadic CJD</td>
<td>NCSE</td>
<td>Yes</td>
<td>PHT, DZP</td>
<td>None</td>
<td>Frequent bilateral epileptiform activity (not described in detail)</td>
<td>NA</td>
<td>Died 2 weeks after onset of SE</td>
</tr>
<tr>
<td>Ogawa et al. [108]</td>
<td>F</td>
<td>61</td>
<td>Probable sporadic CJD</td>
<td>Focal non-motor with impaired awareness and hand automatisms</td>
<td>Yes</td>
<td>DZP</td>
<td>None</td>
<td>Left PLEDs</td>
<td>DWI hyperintensities in bilateral caudates, putamens, left F cortex and insula</td>
<td>Death after 3 months from onset</td>
</tr>
</tbody>
</table>
Table 2. Overview of published cases with prion diseases and epilepsy (continued).

<table>
<thead>
<tr>
<th>Reference</th>
<th>Sex (M/F)</th>
<th>Age at observation</th>
<th>Diagnosis</th>
<th>Seizure type</th>
<th>Epilepsy as presenting symptom?</th>
<th>Treatment</th>
<th>Response to treatment</th>
<th>EEG</th>
<th>Imaging (MRI)</th>
<th>Clinical course/ follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neufeld et al. [109]</td>
<td>M</td>
<td>62</td>
<td>E200K CJD</td>
<td>Convulsive SE (focal motor and generalized TC seizures)</td>
<td>No</td>
<td>PHT, PB, VPA</td>
<td>Partial</td>
<td>Right PLEDs</td>
<td>Several small hyperintense lesions in both white and grey matter on T2-weighted sequences</td>
<td>Death after 1 mo from SE</td>
</tr>
<tr>
<td>Miyake et al. [110]</td>
<td>F</td>
<td>79</td>
<td>Definite CJD with AD pathology</td>
<td>Tonic focal, then NCSE</td>
<td>No</td>
<td>VPA, LEV, PHT, DZP</td>
<td>None</td>
<td>Focal Sp and slow W bursts in the bilateral F areas. Follow-up: left PLEDs</td>
<td>Cortical ribboning, increased signal in left basal ganglia, severe bilateral hippocampal atrophy</td>
<td>Died at 82 y</td>
</tr>
<tr>
<td>Mahboob et al. [75]</td>
<td>M</td>
<td>60</td>
<td>Probable sporadic CJD</td>
<td>Focal clonic, then NCSE</td>
<td>Yes</td>
<td>LEV, LCM, steroids, VPA, PER, PB</td>
<td>None</td>
<td>Continuous left F and sometimes bifrontal sharp Sp (NCSE). Follow-up: PSWC</td>
<td>Cortical ribboning, limited involvement of the basal ganglia</td>
<td>Died 26 days after admission</td>
</tr>
<tr>
<td>Lee et al. [70]</td>
<td>M</td>
<td>42</td>
<td>Probable sporadic CJD</td>
<td>Focal clonic of right arm, EPC</td>
<td>Yes with dementia</td>
<td>VPA, TPM, GBP, LTG, LOR</td>
<td>None</td>
<td>Onset sharp and slow-W complexes in the left hemisphere. Follow-up: left hemispheric PLEDs pattern</td>
<td>FLAIR hyperintensity left O cortex</td>
<td>NA</td>
</tr>
<tr>
<td>Karatas et al. [111]</td>
<td>F</td>
<td>66</td>
<td>Probable sporadic CJD</td>
<td>GTC</td>
<td>No</td>
<td>DZP, PB, VPA, thiopental, isoflurane</td>
<td>None</td>
<td>Slow BG with bilateral asymmetric paroxysmal sharp W on P-O regions. On follow-up: PSWC</td>
<td>Brain atrophy. DWI and T2 weighted images hyperintensities in cerebral cortex, bilateral caudate and lentiform nuclei</td>
<td>Death 9 months after onset of symptoms</td>
</tr>
<tr>
<td>Fernández-Torre et al. [112]</td>
<td>F</td>
<td>75</td>
<td>Definite sporadic CJD</td>
<td>NCSE</td>
<td>No</td>
<td>DZP, PHT, VPA, PB, CLZ</td>
<td>Yes</td>
<td>Onset; continuous diffuse Sp, rhythmic sharp W, and sharp-and-slow W complexes. Follow-up: right PLEDs. Follow-up: PSWC</td>
<td>Moderate diffuse cerebral atrophy</td>
<td>Death 50 days after admission</td>
</tr>
<tr>
<td>Espinosa et al. [113]</td>
<td>F</td>
<td>64</td>
<td>Definite sporadic CJD</td>
<td>NCSE</td>
<td>Yes</td>
<td>Propofol, PHT, PB, VPA, TPM, LEV</td>
<td>None</td>
<td>Right PLEDs</td>
<td>FLAIR hyperintensities in right caudate and a few areas of the cerebral white matter</td>
<td>Death after 3 weeks from NCSE onset</td>
</tr>
<tr>
<td>Lowden et al. [114]</td>
<td>F</td>
<td>49</td>
<td>Familiar CJD (E200K-T29M)</td>
<td>EPC, NCSE</td>
<td>Yes</td>
<td>PB, LEV, LGT, ZNS, PHT</td>
<td>None</td>
<td>Right PLEDs. Follow-up: PSWC</td>
<td>Increased T2, FLAIR and diffusion signal involving bilateral caudates, putamens and thalami pulvinars</td>
<td>Died after 2 mo from onset of symptoms</td>
</tr>
<tr>
<td>Reference</td>
<td>Sex</td>
<td>Age at observation (Y)</td>
<td>Diagnosis</td>
<td>Epilepsy presenting symptom(s)</td>
<td>Clinical course/ follow-up</td>
<td>EEG imaging (MRI)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------</td>
<td>-----</td>
<td>------------------------</td>
<td>-----------------</td>
<td>--------------------------------</td>
<td>---------------------------</td>
<td>----------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rakitin et al.</td>
<td>F</td>
<td>47</td>
<td>NCSE sporadic CJD</td>
<td>No</td>
<td>DZP, CBZ, propofol</td>
<td>Restricted diffusion in basal ganglia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Donmez et al.</td>
<td>F</td>
<td>26</td>
<td>NCSE sporadic CJD</td>
<td>No</td>
<td>DZP, VPA, MDZ</td>
<td>Death 80 days after onset of symptoms</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cohen et al.</td>
<td>M</td>
<td>44</td>
<td>NCSE sporadic CJD</td>
<td>No</td>
<td>BDZ, VPA, PB, LEV, OXC, MDZ</td>
<td>Death 35 days after onset</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aigubballa et al.</td>
<td>M</td>
<td>68</td>
<td>NCSE sporadic CJD</td>
<td>No</td>
<td>CLZ, PHT, LEV, MDZ</td>
<td>Restricted diffusion in basal ganglia, PLEDs, followed by GPEs (1 Hz) and then generalised theta activity without GPEs</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aranyi et al.</td>
<td>F</td>
<td>60</td>
<td>NCSE sporadic CJD</td>
<td>No</td>
<td>PUT, PB, CDBZ</td>
<td>None</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kimiski et al.</td>
<td>M</td>
<td>57</td>
<td>NCSE sporadic CJD</td>
<td>No</td>
<td>DZP, VPA, MDZ</td>
<td>Restricted diffusion in basal ganglia, PLEDs, followed by GPEs (1 Hz) and then generalised theta activity without GPEs</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mader et al.</td>
<td>M</td>
<td>61</td>
<td>NCSE sporadic CJD</td>
<td>No</td>
<td>VPA, LOR</td>
<td>Death 2 weeks after admission</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rossati et al.</td>
<td>F</td>
<td>74</td>
<td>NCSE sporadic CJD</td>
<td>No</td>
<td>CLZ, PHT, propofol</td>
<td>Alpha-theta BG with intermittently superimposed irregular Sp.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Table 2.** Overview of published cases with prion diseases and epilepsy (continued).

CJD: Creutzfeldt-Jakob disease; AD: Alzheimer disease; EPC: epilepsia partialis continua; GTC: generalized tonic-clonic; NCS: non convulsive status epilepticus; SE: status epilepticus; GPE: generalised periodic epileptiform discharges; LOR: lorazepam; LCM: lacosamide; PER: perampanel; GBP: gabapentin; ZNS: zonisamide; LOR: lorazepam; PSW: periodic sharp-and-wave complexes; SW: slow waves; PLEDs: periodic lateralized epileptiform discharges; W: waves; Sp: spikes; BG: background; GPEDs: generalised periodic epileptiform discharges; F: frontal; C: central; T: temporal; P: parietal; O: occipital; DWI: diffusion weighted imaging; FLAIR: fluid attenuated inversion recovery; NA: not available.
Dementia with Lewy bodies

Dementia with Lewy bodies (DLB) is the third most common type of dementia after Alzheimer and vascular dementia [76]. Some studies show that the occurrence of seizures in DLB is higher than in the general population with an incidence rate of 2.62% for clinically diagnosed DLB and 3.8% for pathologically confirmed DLB [77]. A large retrospective analysis of seizures in patients with different types of dementia found a cumulative probability of developing seizures in DLB patients of 14.7%, which is higher than that observed in AD [17]. Age at seizure onset varies from 70 to 75 years and seizures may occur within four years before or after dementia onset [17]. The semiology of seizures is poorly reported, although a prevalence of focal or secondary generalized seizures has been observed [17]. As with Alzheimer, however, focal non-motor seizures may be undetected, hidden in the context of the neurocognitive disorder [17].

Regarding treatment, a study aiming to identify effective and safe ASMs in DLB patients concluded that the most suitable first-line drugs were lamotrigine, levetiracetam, lacosamide, brivaracetam, and gabapentin or pregabalin as second line [78]. Pathogenetic studies in animal models of DLB have demonstrated a role of alpha-synuclein in neuronal hyperexcitability [79]. In addition, pathological abnormalities frequently overlap between DLB and AD, such as neurofibrillary tangles and plaques, suggesting common epileptogenic mechanisms in these two conditions [80]. Indeed, the DLB-AD patient group displayed the highest prevalence of seizures (20.7%) [11], and synergistic interactions between the two disease processes have been previously demonstrated in double transgenic mice expressing human synuclein and APP [81].

Fronto-temporal dementia

A retrospective analysis revealed a cumulative probability of developing seizures in patients with fronto-temporal dementia (FTD) of 3.0%, including also patients with progressive supranuclear palsy and cortico-basal degeneration as well as behavioural and linguistic variants of FTD [14]. FTD with parkinsonism linked to chromosome 17 (FTD-17q) has also been associated with epilepsy [82]. Mutations within the tau gene have been shown to cause FTD, demonstrating that tau dysfunction, in the absence of amyloid pathology, can be sufficient to cause neuronal loss and clinical dementia. In tau-negative FTD, TAR DNA-binding protein (TDP43) was identified as the major hallmark of this condition and the aggregation and cytoplasmic translocation of this nuclear protein are considered to contribute to the pathogenesis of FTD syndromes [83].

Tau protein, a hallmark of FTD pathology, has been suggested to play a role in epileptogenesis by modulating neuronal excitability in animal models of AD [84], and the presence of CSF total tau (T-tau) has been associated with a higher risk of developing seizures in humans [85].

Cortico-basal degeneration

A single case report of focal motor seizures in a 65-year-old patient with cortico-basal degeneration (CBD) exists in the literature. No alternative causes were found for her seizures, and the patient responded optimally to levetiracetam [86].

Parkinson disease

The association between Parkinson disease (PD) and epilepsy has always been considered very rare; almost "mutually exclusive" [87]. However, a recent retrospective study investigating the incidence of epileptic seizures in PD concluded that incident PD is associated with an increased risk of incident epileptic seizures [88]. After adjusting for potential confounding factors, a 1.7-fold increased risk of epileptic seizures in patients with PD compared with PD-free individuals was still observed. In particular, the risk was higher in PD patients with comorbid brain disorders, dementia, or more than one seizure provoking comorbidity. These findings are consistent with a cross-sectional study, which reported a prevalence ratio of PD of 3.19 (95% CI: 5.24-4.18) in patients with epilepsy aged more than 16 years, compared with non-epileptic individuals [89]. Interestingly, PD patients with comorbidities, that are known to be risk factors for epileptic seizures, had an even higher risk of epileptic seizures than patients without PD with such comorbidities [88]. Another study [90] reported a marked increase in the rate of SE in patients with idiopathic PD as compared to epilepsy patients, hypothesizing that the functional impairment of the basal ganglia in PD patients makes SE more likely by modulating thalamic nuclei involved in seizure maintenance, and thus suggesting a benefit from dopaminergic treatment in PD patients with SE [90]. An overview of published cases with Parkinson disease and epilepsy is presented in table 3.

A role of the basal ganglia in the propagation and control of epileptic seizures has been postulated [91] and, indeed, high-frequency transient stimulation of the subthalamic nucleus can suppress absence seizures in rats [92]. Further data from animal models and case reports suggest an antiepileptic effect by activation of dopamine receptor type 2, which is mainly
under-stimulated in PD, and a potential protective effect of antiparkinsonian drugs on epileptic seizures [93]. Furthermore, zonisamide, an ASM with a dopaminergic effect, was reported to have beneficial effects on motor dysfunction and fluctuations in PD [94]. On the contrary, antipsychotic drugs that diminish dopaminergic transmission have been shown to facilitate seizures [93]. These data support the concept of a potential association between dopamine and epileptic seizures and emphasize the need for further research to investigate this relationship.

Progressive myoclonus epilepsies

Progressive myoclonus epilepsies (PME) represent a large group of neurodegenerative diseases associated with myoclonus, epilepsy and progressive neurological deterioration; in addition, photosensitivity, even at slow or single flash rates, can be a prominent clinical feature in some PME [94]. The majority are inherited in an autosomal recessive fashion, but autosomal dominant and mitochondrial inheritance are also known. PMEs account for less than 1% of all epilepsies. Age at onset varies from childhood to adult age depending on the specific disease, and the course is invariably fatal in most of these conditions [95]. PMEs comprise a large range of conditions including Unverricht-Lundborg disease, Lafora disease, neuronal ceroid lipofuscinosis, mitochondrial disorders (MERRF, POLG1, MELAS) and sialidosis. An overview of the main clinical and laboratory features of the various PMEs is reported in table 4 and in [95, 96]. In the following section, we summarize the main phenotypic features, pathogenetic mechanisms and treatment approaches for the most common PMEs.

- Unverricht-Lundborg

Unverricht-Lundborg disease (ULD) is the most common cause of PME and is due to a massive downregulation of the CSTB gene (or EPMT) that

![Figure 2. EEG of Case 2 showing slowing of the background activity with some diffuse sharp-slow waves at admission (A), and diffuse periodic sharp-wave complexes (PSWC) at a rate of 1-2 Hz, 10 days after admission (B).](image-url)
encodes for cystatin B [95]. It is considered the least severe form of PME, and in the initial stages of the disease, it can be misdiagnosed as juvenile myoclonic epilepsy [95]. Onset is between 7 and 13 years of age with progressive, stimulus-sensitive action myoclonus, tonic-clonic seizures and absence seizures. By six years after onset, myoclonus tends to worsen and patients develop ataxia and mild cognitive decline. Epilepsy tends to stabilize or even improve in early adulthood, although severely disabling stimulus-sensitive myoclonus and action myoclonus persist. EEG presents with background slowing and stimulus-sensitive myoclonus and action myoclonus in early adulthood, although severely disabling decline. Epilepsy tends to stabilize or even improve in early adulthood, although severely disabling stimulus-sensitive myoclonus and action myoclonus persist. EEG presents with background slowing and marked ictal and interictal generalized spike-waves discharges [95] (figure 3). Photic stimulation may facilitate spike-wave discharges but photosensitivity tends to abate and disappear after 10-15 years [95]. Valproate and levetiracetam are currently considered the most effective medications [95]. In most patients, seizure persistence and uncontrolled myoclonus require polytherapy with multiple ASMs [95]. The pathogenesis of seizures is not fully delineated. Experimental evidence from Cstb knock-out mice has shown that altered expression of cystatin B increases the activity of the protease, cathepsin B, which has the potential to damage neuronal function leading to hyperexcitability of cortical neuronal networks [95]. In addition, Cstb-deficient mice display increased susceptibility to kainate-induced seizures and display more neurodegeneration than controls, with loss of GABAergic hippocampal neurons resulting in defective GABAergic inhibition that leads to hyperexcitability of cortical neuronal networks and seizures [95].

**Lafora disease**

Lafora disease (LD) is due to autosomal recessive loss-of-function mutations in either the EPM2A gene (which encodes for laforin) or EPM2B gene (which encodes for malin) [95]. LD is a glycogen storage disease of which the pathological hallmark is “Lafora bodies” that consist of deposits of polyglucosan, an abnormal type of glycogen [96]. Onset of LD is between 8 and 18 years of age in previously normal adolescents, and is accompanied by cognitive decline, cerebellar signs, visual impairment, stimulus-sensitive myoclonic jerks and generalized seizures. Focal seizures with prevalent visual symptoms are also present. Seizures are drug-resistant and the condition progresses within 10 years to profound dementia and eventually to a vegetative state and death [95]. The EEG may be normal in the very early stages of the disease, then background activity rapidly slows down, generalized interictal spike-wave and polyspike discharges are elicited by photic stimulation, and posteriorly predominant multifocal epileptiform abnormalities appear (figure 4). Generalized discharges become almost continuous in the final stages of the disease [95].

A few ASMs have been shown to act on seizures and myoclonus, but none of them have been shown to affect the course of the disease. Valproate can, at least initially, suppress generalized seizures and photosensitivity, and topiramate and zonisamide may have antitymoclonic effects [95]. A good response to perampanel has also been reported [95].

As for pathogenesis, accumulation of Lafora bodies (LB) in neuronal dendrites could explain the cortical hyperexcitability in LD [95]. Several studies in cellular and animal models have shown that the malin-laforin complex is essential for many processes including glycogen metabolism [95]. Disruption of normal glycogen metabolism can cause hyperexcitability and epileptic seizures by compromising the glyco-genolysis-dependent reuptake of extracellular K⁺ by astrocytes, thereby leading to increased extracellular K⁺ and associated membrane depolarization [95].

**Neuronal ceroid lipofuscinoses**

Neuronal ceroid lipofuscinoses (NCL), also known as Batten disease, comprises a group of neurodegenerative lysosomal storage disorders resulting in excessive accumulation of lipopigments [96]. NCLs are characterized by progressive decline of cognitive and motor functions, retinopathy with evolution to blindness, varying degrees of brain atrophy, and myoclonic epilepsy [95]. There are 14 forms of neuronal ceroid lipofuscinoses, classified according to age of symptom onset (varying from infancy and childhood to adulthood) and causative gene mutation [96]. ASMs commonly used are lamotrigine and valproic acid. Topiramate and levetiracetam can be also effective while carbamazepine, phenytoin and gabapentin may worsen myoclonic seizures [95].

Infantile NCL is a severe disease of infancy, which presents with seizures, developmental arrest and regression, and visual loss. The main gene involved in this form is CLN1, which encodes a lysosomal palmitoyl protein thioesterase. More severe than CLN1 is CLN10, which is a congenital fatal condition characterized by encephalopathy with respiratory insufficiency and status epilepticus. CLN10 encodes the lysosomal protease, cathepsin D [96].

Late-infantile NCL presents with onset in early childhood and is caused by pathogenic variants of the CLN2 gene. This disorder is characterized at the onset by a very severe myoclonic epilepsy, followed during the course of the disease, by cognitive and motor decline, and later by visual loss. CLN2 encodes a lysosomal tripeptidyl peptidase. Other NCLs such as CLN5, CLN6, CLN7, CLN8, and CLN14 mimic, to various extents, the clinical phenotype of the classic CLN2. Mild CLN6 mutations are another cause of
**Table 3.** Overview of published cases with Parkinson disease and epilepsy.

<table>
<thead>
<tr>
<th>Reference</th>
<th>Sex (M/F)</th>
<th>Age at observation mean (range)</th>
<th>Diagnosis</th>
<th>Age at seizure onset mean (range)</th>
<th>Seizure type</th>
<th>EEG</th>
<th>Imaging</th>
<th>Treatment</th>
<th>Response to treatment (Yes/No)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Son et al. [121]</td>
<td>3/2</td>
<td>71y (49-86)</td>
<td>Idiopathic PD</td>
<td>50 y (20-82)</td>
<td>Focal impaired awareness, GTCs</td>
<td>NA</td>
<td>NA</td>
<td>ESL, CBZ, CLZ, LEV, LTG</td>
<td>Yes (4/5)</td>
</tr>
<tr>
<td>Son et al. [122]</td>
<td>0/2</td>
<td>70y (64-76)</td>
<td>Idiopathic PD</td>
<td>76y (70-82)</td>
<td>Discognitive, olfactory hallucinations, visual aura, focal non motor with impaired awareness</td>
<td>Focal spikes, focal slowing, focal spike-waves</td>
<td>CT and MRI normal</td>
<td>LTG, LEV</td>
<td>Yes (2/2)</td>
</tr>
<tr>
<td>Vercueil et al. [87]</td>
<td>1/0</td>
<td>45y</td>
<td>Juvenile Parkinson</td>
<td>At birth (age not specified)</td>
<td>Febrile convulsions (at birth), focal with impaired awareness</td>
<td>NA</td>
<td>NA</td>
<td>PB, CBZ</td>
<td>Yes (seizure decreased after Parkinson onset, seizure free with PB)</td>
</tr>
<tr>
<td>Romdhan et al. [123]</td>
<td>1/0</td>
<td>23y</td>
<td>Juvenile PD (SYNJ1 mutation-related)</td>
<td>7y</td>
<td>GTCs</td>
<td>NA</td>
<td>MRI normal</td>
<td>VPA</td>
<td>Yes</td>
</tr>
<tr>
<td>Feddersen et al. [90]</td>
<td>10/9</td>
<td>73y (55-89)</td>
<td>Idiopathic PD</td>
<td>NA</td>
<td>NCSE, CSE</td>
<td>Hemispheric, focal (frontal and temporal) abnormalities</td>
<td>NA</td>
<td>BZD, CBZ, VPA, TPM, LEV, PHT, PB, GBP, OXC, PROP, LTG</td>
<td>Yes (14/19)</td>
</tr>
</tbody>
</table>

PD: Parkinson disease; GTCs: generalized tonic-clonic seizures; NCSE: non convulsive status epilepticus; CSE: convulsive status epilepticus; ESL: eslicarbazepine; CBZ: carbamazepine; CLZ: clonazepam; LEV: levetiracetam; LTG: lamotrigine; PB: phenobarbital; VPA: valproic acid; BZD: benzodiazepine; TPM: topiramate; PHT: phenytoin; GBP: gabapentin, OXC: oxcarbazepine, PROP: propofol.
Table 4. Main features of progressive myoclonic epilepsies.

<table>
<thead>
<tr>
<th>PME</th>
<th>Age at onset (years)</th>
<th>Genetics</th>
<th>Pathology</th>
<th>Pathophysiology</th>
<th>Signs and symptoms</th>
<th>EEG</th>
<th>Prognosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unverricht-Lundborg (EPM1)</td>
<td>6-18</td>
<td>EPM1 - 21q22.3</td>
<td>None</td>
<td>Reduced cystatin B (CSTB) expression, increased cathepsin B activity, impaired redox homeostasis, apoptotic cell death. Impairment of GABAergic inhibitory neurotransmission, loss of cortical GABA terminals.</td>
<td>Seizures, action-activated stimulus sensitive myoclonus. Ataxia, dysarthria and poor coordination. Absent to moderate cognitive impairment</td>
<td>Early stages: normal BG, SW and pSW. Photosensitivity (90%). Sleep patterns maintained, anomalies aggravated during REM sleep. Follow-up: anomalies diminish; photosensitivity and SW discharges disappear after 15 years.</td>
<td>Symptoms progress slowly then stabilize in adulthood. Severe in a minority of cases.</td>
</tr>
<tr>
<td>Scarb2/LIMP2 variant</td>
<td>15-25</td>
<td>Scarb2/LIMP2 gene - 4q13-21</td>
<td>None</td>
<td>Diffuse neuronal loss and gliosis including pallidolusyan and cerebellar-olivary system</td>
<td>Seizures, myoclonus, tremor, ataxia, renal failure/nephritic syndrome. Cases without renal failure have been reported.</td>
<td>Similar to ULD</td>
<td>Severe in most cases</td>
</tr>
<tr>
<td>PRICKLE variant</td>
<td>5-10</td>
<td>PRICKLE1 gene - 12q12</td>
<td>None</td>
<td>Unclear</td>
<td>Ataxia at onset, action myoclonus, seizures</td>
<td>Similar to ULD</td>
<td>Intellect preserved</td>
</tr>
<tr>
<td>MEAK (myoclonus epilepsy and ataxia due to potassium channel mutation)</td>
<td>3-15</td>
<td>KCNC11 c.959G&gt;A de novo mutations</td>
<td>None</td>
<td>Disruption of function of KV3 voltage-gated potassium ion channels</td>
<td>Early-onset, progressively severe myoclonus, TC seizures. Mild cognitive decline. Improvement with fever.</td>
<td>Similar to ULD</td>
<td>Wheelchair-bound by late teenage years, preservation of intellect</td>
</tr>
<tr>
<td>North Sea PME</td>
<td>2-5</td>
<td>GOSR2</td>
<td>None</td>
<td>Reduction in SNARE-mediated membrane fusion, impaired dendritic growth. Fragmentation of presynaptic cytoskeleton, trans synaptic instability, hyperactive neurotransmission.</td>
<td>Early onset ataxia, areflexia, action myoclonus, seizures (TC, absences, drop attacks), scoliosis, elevated creatine kinase levels.</td>
<td>Generalized SW discharges, posterior predominance. Photosensitivity</td>
<td>Preservation of intellect, wheelchair-bound since adolescence, death in adult age</td>
</tr>
<tr>
<td>PME</td>
<td>Age at onset (years)</td>
<td>Genetics</td>
<td>Pathology</td>
<td>Pathophysiology</td>
<td>Signs and symptoms</td>
<td>EEG</td>
<td>Prognosis</td>
</tr>
<tr>
<td>------------------------------------------</td>
<td>----------------------</td>
<td>-----------------------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Lafora disease (EPM2)</td>
<td>6-19</td>
<td>EPM2A (encoding laforin) EPM2B (encoding malin)</td>
<td>LB (polyglucosans) accumulation in CNS, hepatic parenchyma, striated and cardiac muscles, sweat gland ducts</td>
<td>Disruption of normal glycogen metabolism that causes hyperexcitability and epileptic seizures by compromising the glycogenolysis-dependent reuptake of extracellular K+ by astrocytes</td>
<td>TC, M, myoclonic seizures, absences, focal visual seizures. Severe resting and action myoclonus, ataxia, depression, rapid course of dementia,</td>
<td>At onset: normal BG, isolated SW, diffuse 4-6 Hz pSW discharges. Photosensitivity. Within a few months: slow BG activity, focal occipital epileptiform anomalies, fast SWs and pSWs, sleep patterns disappear. Erratic myoclonus recorded.</td>
<td>Very severe. Death within 2-10 years.</td>
</tr>
<tr>
<td>Late infantile ceroid lipofuscinosis</td>
<td>1-4</td>
<td>CLN2, CLN5 (Finnish variant), CLN6 (Gypsy variant), CLN7, CLN8</td>
<td>Storage of lipopigments in lysosomes. Curvilinear granular inclusions in neurons, skin, peripheral nerves, muscles</td>
<td>Accumulation of autofluorescent storage material (AFSM), dysregulated autophagy, progressive glial activation, neuronal death, interneuron loss within the cortex and hippocampus.</td>
<td>Locomotor impairment, ataxia, speech disorder, psychomotor regression, TC seizures, myoclonus. Gradual blindness with optic atrophy.</td>
<td>Slow BG activity, burst of S and pSW. Posterior polyphasic spikes elicited by low frequency flash stimuli.</td>
<td>Severe.</td>
</tr>
<tr>
<td>Juvenile ceroid lipofuscinosis (Spielmeyer-Vogt)</td>
<td>4-14</td>
<td>CLN3, CLN9</td>
<td>Storage of lipopigments in lysosomes. Curvilinear granular inclusions and fingerprint profiles in neurons, skin, lymphocytes</td>
<td>Like Jansky-Bielschowsky</td>
<td>Retinitis pigmentosa, cognitive impairment, ataxia, extrapyramidal and pyramidal signs, dysarthria. Absence, myoclonic, TC seizures, clonic status epilepticus. Psychotic episodes.</td>
<td>Slow BG activity, paroxysmal bursts enhanced in sleep,</td>
<td>Severe.</td>
</tr>
<tr>
<td>Adult ceroid lipofuscinosis (Kufs)</td>
<td>11-50</td>
<td>CLN6</td>
<td>Fingerprint profiles and osmiophilic granular profiles in neurons, skin, liver</td>
<td>Like Jansky-Bielschowsky</td>
<td>Dementia, ataxia, dyskinesia, athetosis, seizures, myoclonus</td>
<td>Slow BG with generalized SW discharges, photosensitivity</td>
<td>Usually severe</td>
</tr>
<tr>
<td>Myoclonic epilepsy with ragged-red fibres (MERRF)</td>
<td>3-65</td>
<td>Mitochondrial DNA mutations</td>
<td>Ragged red fibres on light microscopy</td>
<td>Respiratory metabolic chain deficits, ROS accumulation</td>
<td>Variability of clinical presentation: seizures, ataxia, myoclonus, deafness, myopathy, lactic acidosis, optic</td>
<td>SW discharges and generalized pSW, diffuse delta bursts, photosensitivity</td>
<td>Variable from very mild to very severe</td>
</tr>
</tbody>
</table>
**Table 4.** Main features of progressive myoclonic epilepsies (continued).

<table>
<thead>
<tr>
<th>PME</th>
<th>Age at onset (years)</th>
<th>Genetics</th>
<th>Pathology</th>
<th>Pathophysiology</th>
<th>Signs and symptoms</th>
<th>EEG</th>
<th>Prognosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sialidosis (type 1)</td>
<td>8-25</td>
<td>NEU1 (α-neuraminidase)</td>
<td>Cytoplasmic vacuolation in neurons and perineuronal and interlaminar oligodendroglia, endothelial and perithelial cells</td>
<td>Neuronal intracytoplasmic storage of lipofuscin-like pigment, premature degradation of molecules implied in various cellular activities</td>
<td>Seizures, myoclonus prominently facial, visual deficit, developmental delay, ataxia, “burning hands and feet”</td>
<td>Normal BG, SW discharges during myoclonias</td>
<td>Variable, sometimes benign. Intellect preserved in most.</td>
</tr>
<tr>
<td>Sialidosis type 2 (congenital, infantile or juvenile)</td>
<td>Earlier than type 1</td>
<td>NEU1 (α-neuraminidase)</td>
<td>Like Type 1</td>
<td>Like type 1 plus skeletal changes, coarse face</td>
<td>Like Type 1</td>
<td>Severe in most cases</td>
<td></td>
</tr>
<tr>
<td>Galactosialidosis (late infantile, juvenile)</td>
<td>Early childhood, adolescence or later</td>
<td>PPCA (ptorein/cathepsin A)</td>
<td>Cytoplasmic vacuolation in neurons and perineuronal and interlaminar oligodendroglia, endothelial and perithelial cells</td>
<td>Neuroaminidase and β-galactosidase inactivation, by lysosomes, neuronal intracytoplasmic storage of lipofuscin-like pigment, premature degradation of molecules implied in various cellular activities</td>
<td>Ataxia, coarse facial features, bone changes, mild intellectual disability, memory loss, rare seizures (late infantile form).</td>
<td>Like sialidosis</td>
<td>Usually severe</td>
</tr>
<tr>
<td>Dentato-rubro-pallido-luysian atrophy (DRPLA)</td>
<td>6-69</td>
<td>Unstable CAG expansion of atrophin gene, genetic anticipation is possible</td>
<td>None</td>
<td>Unclear, diffuse accumulation of mutant protein atrophin-1 in neuronal nuclei, neuronal death</td>
<td>Seizures, myoclonus, ataxia, choreoathetosis, psychosis, dementia</td>
<td>Slow bursts, generalized SW discharges</td>
<td>Variable but often severe</td>
</tr>
<tr>
<td>Gaucher disease (type III)</td>
<td>Variable</td>
<td>GBA (glucosidase beta acid)</td>
<td>Accumulation of glucocerebroside</td>
<td>Accumulation of glucocerebroside</td>
<td>Seizures, myoclonus, ataxia, moderate intellectual impairment, saccadic horizontal eye movements, supranuclear gaze paralysis, hearing abnormalities</td>
<td>Bursts of posterior or multifocal S or pSW, photosensitivity,</td>
<td>Variable, severe in most cases</td>
</tr>
</tbody>
</table>

ULD: Unverricht-Lundborg disease; BG: background; SW: spike-waves; pSW: polyspike-waves; S: spikes; REM: rapid eye movement; TC: tonic-clonic; T: tonic; M: myoclonus; LB: Lafora Bodies; ROS: reactive oxygen species.
**Figure 3.** Male, 17 years of age, suffering from Unverricht-Lundborg disease. The interictal EEG shows discrete background slowing, generalized paroxysmal discharges of spikes/polyspikes and slow waves as well as irregular 2.5-4.5-Hz activity, maximum in amplitude in the (right) fronto-prefrontal region. Epileptiform discharge elicited by 18-Hz intermittent photic stimulation correlates with myoclonic jerks in the upper extremities.

**Figure 4.** Female, 15 years of age, with Lafora body disease. The interictal EEG shows discrete background slowing, irregular 3.5-4-Hz activity, intermixed spike-and-slow waves in the occipital regions (left side predominance), as well as short trains of 2.5-Hz generalized polyspikes and slow waves, with left occipito-post-temporal onset.
adolescence or adult-onset PME [96]. \textit{CLN6} encodes an endoplasmic reticulum protein of unclear function. The main features of juvenile NCL (CLN3) are onset in later childhood with retinal pathology and visual loss which are often the only symptoms for some years. Neurocognitive and motor decline eventually appear as well as seizures and myoclonus, the latter two present in a mild form for long periods. \textit{CLN3} encodes a lysosomal membrane protein with multiple attributed functions, including palmitoyl protein desaturase activity.

The onset of CLN4 (with mutation in the \textit{DNAJC5} gene; the only autosomal dominant NCL), CLN11 [96] and CLN13 (with mutation in the \textit{CTSF} gene encoding lysosomal cathepsin F) occur in adulthood. CLN11 (with mutation in the \textit{GRN} gene encoding the progranulin protein), similar to CLN3, presents with a prolonged period of severe visual impairment before the appearance of the PME phenotype [96]. Interestingly, other \textit{GRN} mutations underlie completely distinct non-PME neurodegenerative disorders, such as frontotemporal dementia with TDP43-positive inclusions. CLN12 (with mutation in the \textit{ATPI3A2} gene) can present with variable phenotypes, including teenage-onset PME, with some levodopa-responsive extrapyramidal features and one type of juvenile-onset Parkinson disease (PARK9; Kufor–Rakeb disease) [96]. CLN13 does not present as a PME since it is essentially a neurodegenerative disease with ataxia and dementia [96].

**Concluding remarks**

Epilepsy can be a comorbidity of some of the most common neurodegenerative pathologies and as the global population ages, the intersection between ageing, epilepsy and neurodegenerative disorders will become an increasingly pressing concern. Nevertheless, it is surprising to see to what extent epilepsy in neurodegenerative disorders remains underestimated. Studies in the elderly have supported the concept of a bidirectional association between dementia and epilepsy: indeed, not only do people with a dementing illness such as AD have an increased risk of subsequent epilepsy, but people with epilepsy are at a substantially increased risk of developing dementia.

Current evidence suggests that a process beginning long before the onset of clinically apparent seizures can potentially drive both epileptogenesis and cognitive decline. Yet, the role of epileptogenesis, either as the underlying culprit or as a consequence of neurodegeneration, remains unclear. Future avenues of research should clarify these mechanisms and investigate whether novel pharmacological therapies that target neurobiological pathways underpinning neurodegenerative diseases might potentially have anti-epileptogenic and disease-modifying effects on the seizures as well as on the progressive neurocognitive deterioration.

Neurologists will probably deal with these diseases to a growing extent in the future and understanding the epidemiology and the pathophysiology of epilepsy and degenerative disorders, particularly those affecting the elderly, might help to shape health care policies and reduce the burden of disease.

**Supplementary material.**

Summary slides accompanying the manuscript are available at www.epilepticdisorders.com.

**Disclosures.**

None of the authors have any conflicts of interest related to this study to disclose.

**Key points**

- Epilepsy can be a comorbidity in several neurodegenerative diseases. On the other hand, neurodegenerative diseases are considered to account for about 10% of late-onset epilepsies.
- The probability of developing seizures in Alzheimer disease (AD) has been estimated to be around 13%. This percentage increases in patients presenting with early-onset AD.
- In AD, experimental data suggest that cognitive decline and seizures might share some common pathophysiological mechanisms and reciprocally influence one another.
- Patients presenting with Down syndrome may start to suffer from a dementing process in the third decade of life. More than 50% of these patients will likely develop epilepsy.
- Epilepsy appears to be a rare comorbidity in prion diseases.
- Recent data suggest an increased risk of epileptic seizures in patients with Parkinson disease (PD) as compared to PD-free subjects of the same age.
- As the global population ages, neurologists will deal with epilepsy in degenerative disorders to a growing extent.

**References**


91. Vuong J, Devergnas A. The role of the basal ganglia in the control of seizure. J Neural Transm (Vienna 2018; 125(3): 531-45.


TEST YOURSELF

(1) In which of these neurodegenerative diseases is epileptic photosensitivity a prominent clinical and EEG feature?
   A. Parkinson disease
   B. Dementia with Lewy bodies
   C. Unverricht-Lundborg disease

(2) What are the most commonly reported types of seizures in Alzheimer disease?
   A. Generalized tonic-clonic seizures
   B. Focal seizures with impaired awareness
   C. Non-convulsive status epilepticus

(3) What can be considered a possible ictal sign compatible with epileptic seizures in a patient with Alzheimer disease?
   A. Agitation/aggression
   B. Repetitive questioning
   C. Wandering behaviour

(4) Which of the following is true regarding late-onset epilepsy in patients with Down syndrome?
   A. It is an epileptic disorder, with predominant myoclonic features and a clinical course similar to that of progressive myoclonic epilepsies
   B. It does not exist; patients with DS do not develop epilepsy after 50 years
   C. It is associated with fronto-temporal dementia

(5) Which one of the following is true regarding characteristics of myoclonus in the advanced stages of Down syndrome?
   A. Myoclonus in advanced stages of Down syndrome always displays an EEG correlate
   B. Myoclonus in advanced stages of Down syndrome never displays an EEG correlate
   C. Myoclonus in advanced stages of Down syndrome can present with or without an EEG correlate

(6) Which of the following is false regarding seizures in prion disease?
   A. Seizures can precede the onset of clinical prion symptoms
   B. Seizure freedom with ASMs is often achieved
   C. Non-convulsive status epilepticus is the most frequently reported type of seizure

(7) Which of the following items can be helpful to discriminate between alteration of consciousness due to non-convulsive status epilepticus and altered mental status typical of the advanced stages of prion diseases?
   A. Clinical and EEG improvement after benzodiazepine
   B. MRI imaging
   C. EEG-EMG polygraphy

(8) The incidence of epilepsy in Parkinson disease is:
   A. reduced compared to the age-matched general population
   B. increased compared to the age-matched general population
   C. the same compared to the age-matched general population

(9) Which PME is associated with focal visual seizures and polyglucosan deposits in neuronal dendrites?
   A. Lafora disease
   B. Type 1 sialidosis
   C. Unverricht-Lundborg disease

(10) In late-infantile neuronal ceroid lipofuscinosis, visual loss:
    A. is the presenting symptom
    B. is not a feature of the disease
    C. occurs later in the course of the disease
(11) **Neurodegenerative diseases account for:**
   A. about 10% of late-onset epilepsies
   B. about 30% of late onset epilepsies
   C. about 50% of late onset epilepsies

(12) **Is epilepsy a common comorbidity in prion diseases?**
   A. False
   B. True

(13) **The probability of developing seizures in Alzheimer disease is greater in:**
   A. late-onset AD
   B. early-onset AD

*Note: Reading the manuscript provides an answer to all questions. Correct answers may be accessed on the website, www.epilepticdisorders.com.*